--- title: APAC trial-share estimates run from 19% to 35% while India's CRO capacity stays thin in 2026 slug: apac-trial-share-estimates-run-from-19-to-35-while-india-s-cro-capacity-stays-thin-in-2026-cro site: cro post_kind: deep_dive byline: Carlton Hoyt description: Anyone building an Asia-Pacific shortlist this year will meet a confident claim that the region is the growth engine of clinical development. Almost nobody in the evidence will tell you how much of… canonical_url: https://www.cro.directory/posts/apac-trial-share-estimates-run-from-19-to-35-while-india-s-cro-capacity-stays-thin-in-2026-cro published_at: 2026-11-10T05:01:21.605Z last_updated: 2026-11-10T05:01:23.848Z --- Anyone building an Asia-Pacific shortlist this year will meet a confident claim that the region is the growth engine of clinical development. Almost nobody in the evidence will tell you how much of that growth is deliverable capacity, and how much is forecast. Before you award, separate the two. The sources agree on direction and disagree on almost everything else. None of them measures spare capacity, meaning how many experienced monitors, project managers, and trial-ready participants a CRO can actually add this year. A headline claiming APAC capacity is "outpacing global demand" would go further than any of the eight sources supports. What the evidence does support is narrower and more useful for a buyer: demand is rising fast, countries differ sharply in how well they can absorb it, and the CROs that look similar on a capabilities slide may not be similar on delivery. ## The regional share is a range, not a number Take the simplest question: how much of global clinical trial activity happens in Asia-Pacific? One analysis puts it at [about 19 per cent today](https://www.pharmafocusasia.com/strategy/asia-pasific-cro-market-analysis), expected to reach 30 per cent within five years. Another market report says the region already contributes [over 35% of global trials](https://www.globalgrowthinsights.com/market-reports/cro-in-clinical-trials-market-109157). That is nearly a twofold gap on a present-tense fact. The likely explanation is definitional. Counting trials with any APAC site, counting trials run primarily in the region, counting patients enrolled, and counting spend all give different answers. The sources don't say which method they use, and a buyer shouldn't assume they match. Treat any share figure in a vendor pitch as marketing until the vendor shows its denominator. Market-size figures show the same problem. One forecaster values the Asia-Pacific clinical trials market at [USD 5.32 billion in 2025](https://www.marketdataforecast.com/market-reports/apac-clinical-trials-market), growing to USD 11.45 billion by 2034. A trade-press outlook describes the region's trials market as [roughly $11 billion to $12 billion](https://www.clinicalleader.com/doc/cro-industry-outlook-the-next-stage-of-clinical-trial-transformation-0001) in 2024, projected to double by the early 2030s. Both say "doubling," but they start from bases that differ by more than a factor of two. The CRO services figures sit in their own frame: [USD 8.59 billion in 2026](https://www.marketdataforecast.com/market-reports/asia-pacific-contract-research-organization-services-market), on an 8.34% CAGR to 2034. Even the growth rates conflict. That CRO-services CAGR sits well below the [12.8 per cent global CRO CAGR](https://www.pharmafocusasia.com/strategy/asia-pasific-cro-market-analysis) cited elsewhere, which would imply the region's CRO revenue grows more slowly than the global market. That sits awkwardly beside the claim that its trial share is rising. One reconciliation is that share gains come from sponsors' own trial placement and pricing pressure rather than from CRO revenue growth. Another is that the datasets are simply not comparable. The sources don't resolve it. What a buyer can take from this: the direction is reliable, the magnitudes are not, and none of these reports should be used to justify a capacity commitment on its own. ## China is a multiregional-execution question, not just a cost one The region's growth story is led by China. BioSpace, drawing on L.E.K. analysis, reports that [in-China trial volume has risen](https://www.biospace.com/drug-development/cro-boom-in-apac-region-with-china-at-the-forefront) rapidly compared with the U.S. and Europe, positioning the country as a major global player in clinical development. The article ties this to multinational pharma acquiring early-stage Chinese assets, and notes that the trend raises demand for CROs with high-quality global systems, regulatory know-how, and multiregional execution capabilities to support cross-border development. This has a practical consequence for how you shortlist. If your program has a China-originated asset, the question is less "which CRO has the most staff in China" and more "which CRO can run one coherent program across China and the rest of the world." That means shared data standards, one set of quality systems, and a regulatory team that understands both the local filing and the FDA or EMA package that will eventually follow. A local specialist may be faster and cheaper inside China and weaker at the handoff. A global CRO may have the systems but thin local depth. The BioSpace framing suggests the premium is on the combination, and that is where you should push on evidence. Be cautious about how far to extend this. The source describes demand-side conditions and gives no data on how any specific CRO performs on cross-border programs. Treat it as a reason to ask the question, not as a ranking. ## India shows how a friendly regulator and thin delivery can coexist If China shows volume, India shows the gap between regulatory intent and delivery capacity. A regional analysis points to a 2026 amendment introducing a ["prior intimation" pathway](https://biopharmaapac.com/analysis/31/8110/beyond-the-obvious-giant-where-apacs-clinical-trials-go-next.html) for low-risk bioavailability and bioequivalence studies, which it reads as a regulator still cutting friction. But the same piece argues that delivery lags. India holds 18 percent of the world's population yet hosts an estimated 5–6 percent of global trials. By industry estimates, 30–40 percent of Indian Phase I studies hit enrolment delays, because CROs compete for a limited pool of trial-ready participants concentrated in a handful of metro sites. That is the clearest capacity signal in the evidence pack, and it points the opposite way from the "capacity is abundant" story. In a market where participant supply is the constraint, adding CRO headcount does not fix the problem. Sponsors who award early-phase work on the strength of a favorable regulatory change, without checking participant access, may find themselves in the 30–40 percent. The practical test is simple. Ask a CRO how many of its last Phase I studies in the country started enrolling on schedule, and from which sites. If the answer is "all of them" and the sites are the same three metro units its competitors use, ask what happens when two of your studies and two of a competitor's land on that pool in the same quarter. ## Audit performance is the measure that cuts through the claims How do you tell a credible regional operator from a confident one? Ken Lee of [Syneos Health](/companies/syneoshealth), whose firm has [around 5,000 staff in the region](https://pharmaboardroom.com/articles/asias-top-clinical-trial-hubs-in-2026-what-to-know/), argues that audit performance is the measure that matters when assessing whether Asian hubs can meet global standards. That is a vendor executive speaking, and the excerpt doesn't give the underlying audit data, so treat it as a framing rather than proof. But the framing is right for a buyer, and it is something you can test. Headcount, site counts, and market-size charts describe potential. Audit and inspection history describes behavior. A CRO that can show clean sponsor audits and regulatory inspection outcomes for its APAC operations, by country, tells you more than any capacity statement. ## Questions worth putting in the next APAC RFP Use the gaps in the evidence to shape what you ask. Each of these requires a vendor to give you something checkable. - **Define the denominator.** When a bidder cites APAC share, patients, or trial counts, ask which measure it uses and for what period. - **Break capacity out by country.** Ask for named, dedicated staff in each country, not a regional total. Ask for turnover and tenure for monitors and project managers in the same places. - **Ask for enrollment-versus-plan data.** Request on-time start and enrollment performance for comparable studies in the last 24 months. For early-phase work in India, ask specifically about participant database size and source. - **Test the cross-border handoff.** If the program spans China and the West, ask who owns data standards, safety reporting, and regulatory strategy across regions, and how many programs have run that way. - **Request audit history by country.** Sponsor audit outcomes and inspection findings for the specific operating units that would run your study, not the global parent. - **Ask what happens at the capacity limit.** If your study and a competitor's collide on the same sites, what is the vendor's mitigation, and will it name the alternates? - **Price the delays.** Ask the vendor to quote with and without the delay assumptions it uses internally. A bid that assumes a 100% on-time start in a market with known enrolment delays is a pricing risk to you. ## What to believe Believe that Asia-Pacific is taking a growing share of global trial activity. Every source agrees on that. Do not believe any specific share, market-size number, or growth rate without seeing its basis, because the sources contradict one another by wide margins. And do not believe that regulatory reform alone equals delivery capacity. India's 2026 amendment shows a regulator cutting friction, while the participant pool remains the bottleneck. The evidence here is thin where it matters most to a buyer: there is no independent measure of CRO utilization, staff availability, or site-level capacity by country. Several of the figures come from market-research vendors who publish forecasts, not audited data. Use them to frame your questions, then make bidders answer with their own operational numbers. ## Sources 1. [CRO Boom in APAC Region,](https://www.biospace.com/drug-development/cro-boom-in-apac-region-with-china-at-the-forefront) With China at the Forefront – BioSpace 2. [Asia's Top Clinical Trial Hubs](https://pharmaboardroom.com/articles/asias-top-clinical-trial-hubs-in-2026-what-to-know/) in 2026: What to Know – PharmaBoardroom 3. [Asia-Pacific CRO Services Market Size](https://www.marketdataforecast.com/market-reports/asia-pacific-contract-research-organization-services-market) & Growth Report, 2034 – Market Data Forecast 4. [Asia Pacific Clinical Trials Market](https://www.marketdataforecast.com/market-reports/apac-clinical-trials-market) Size & Share, 2034 – Market Data Forecast 5. [Asia Pacific CRO Market Analysis – PharmaFocus Asia](https://www.pharmafocusasia.com/strategy/asia-pasific-cro-market-analysis) 6. [CRO Industry Outlook 2026 – Clinical Leader](https://www.clinicalleader.com/doc/cro-industry-outlook-the-next-stage-of-clinical-trial-transformation-0001) 7. Beyond the [Obvious Giant: Where APAC's Clinical](https://biopharmaapac.com/analysis/31/8110/beyond-the-obvious-giant-where-apacs-clinical-trials-go-next.html) Trials Go Next – BioPharma APAC 8. CRO [in Clinical Trials Market Size](https://www.globalgrowthinsights.com/market-reports/cro-in-clinical-trials-market-109157) & Trends 2026 – Global Growth Insights Source: https://www.cro.directory/posts/apac-trial-share-estimates-run-from-19-to-35-while-india-s-cro-capacity-stays-thin-in-2026-cro